JP2007502287A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007502287A5 JP2007502287A5 JP2006523335A JP2006523335A JP2007502287A5 JP 2007502287 A5 JP2007502287 A5 JP 2007502287A5 JP 2006523335 A JP2006523335 A JP 2006523335A JP 2006523335 A JP2006523335 A JP 2006523335A JP 2007502287 A5 JP2007502287 A5 JP 2007502287A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic
- prophylactic agent
- tautomer
- prodrug
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 230000000069 prophylactic effect Effects 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 208000030814 Eating disease Diseases 0.000 claims 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 235000014632 disordered eating Nutrition 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 101800002739 Melanin-concentrating hormone Proteins 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 claims 1
- 102000047659 melanin-concentrating hormone Human genes 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
Claims (5)
- 請求項1〜19のいずれか一項に記載の化合物、薬学的に許容できる塩、互変異性体もしくはプロドラッグまたは請求項20の薬学的組成物を有効成分とする、メラニン凝集ホルモン媒介障害の治療または予防剤。
- 請求項1〜19のいずれか一項に記載の化合物、薬学的に許容できる塩、互変異性体もしくはプロドラッグまたは請求項20の薬学的組成物を有効成分とする、摂食障害、性障害、生殖障害、うつ病、不安、てんかん発作、高血圧、脳出血、うっ血性心不全および睡眠障害からなる群より選択される状態の治療または予防剤。
- 状態が摂食障害である、請求項22の治療または予防剤。
- 摂食障害が肥満、過食症および神経性大食症からなる群より選択される、請求項23の治療または予防剤。
- 請求項1〜19のいずれか一項に記載の化合物、薬学的に許容できる塩、互変異性体またはプロドラッグを有効成分とする、肥満の治療または予防剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49473503P | 2003-08-13 | 2003-08-13 | |
PCT/US2004/026021 WO2005019167A2 (en) | 2003-08-13 | 2004-08-11 | Melanin concentrating hormone receptor antagonist |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007502287A JP2007502287A (ja) | 2007-02-08 |
JP2007502287A5 true JP2007502287A5 (ja) | 2007-06-28 |
Family
ID=34215897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006523335A Withdrawn JP2007502287A (ja) | 2003-08-13 | 2004-08-11 | メラニン凝集ホルモン受容体アンタゴニスト |
Country Status (7)
Country | Link |
---|---|
US (2) | US7514438B2 (ja) |
EP (1) | EP1653960A4 (ja) |
JP (1) | JP2007502287A (ja) |
AU (1) | AU2004266233A1 (ja) |
CA (1) | CA2533112A1 (ja) |
MX (1) | MXPA06001636A (ja) |
WO (1) | WO2005019167A2 (ja) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101157272B1 (ko) | 2003-07-22 | 2012-06-15 | 아레나 파마슈티칼스, 인크. | 5?ht2a 세로토닌 수용체의 조절자로서 이와 관련된질환의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴우레아 유도체 |
EP1902014A2 (en) | 2005-07-11 | 2008-03-26 | Wyeth | Glutamate aggrecanase inhibitors |
TW200800306A (en) * | 2005-09-12 | 2008-01-01 | Wyeth Corp | Sustained-release formulation and uses thereof |
GT200600416A (es) * | 2005-09-12 | 2007-09-20 | Sales salicilato y gentisato de un compuesto de piperazina | |
GT200600414A (es) * | 2005-09-12 | 2007-09-20 | Sal de glucuranato de compuesto de piperazine | |
ATE429428T1 (de) | 2005-09-30 | 2009-05-15 | Hoffmann La Roche | Indanderivate als antagonisten des mch-rezeptors |
PE20070526A1 (es) | 2005-10-13 | 2007-06-11 | Wyeth Corp | Metodos para preparar derivados de acido glutamico |
US20090018142A9 (en) * | 2006-05-02 | 2009-01-15 | Zhengping Zhuang | Use of phosphatases to treat tumors overexpressing N-CoR |
EP2027087A2 (en) | 2006-05-18 | 2009-02-25 | MannKind Corporation | Intracellular kinase inhibitors |
TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物 |
WO2008086069A1 (en) * | 2007-01-03 | 2008-07-17 | The General Hospital Corporation | Methods of treating itch |
AU2008214299B2 (en) | 2007-02-06 | 2014-01-09 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US9567327B2 (en) | 2007-08-15 | 2017-02-14 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
EA018618B1 (ru) | 2007-10-01 | 2013-09-30 | Ликсте Байотекнолоджи, Инк. | Ингибиторы hdac |
US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
CA2730148C (en) | 2008-08-01 | 2018-04-03 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
US8227473B2 (en) | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
CN104784173B (zh) | 2008-10-28 | 2019-07-26 | 艾尼纳制药公司 | 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物 |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
US8673920B2 (en) * | 2009-05-06 | 2014-03-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US9073882B2 (en) | 2010-10-27 | 2015-07-07 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US9056859B2 (en) | 2010-10-29 | 2015-06-16 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
EP2744499B1 (en) | 2011-08-19 | 2016-09-28 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
TW201317213A (zh) | 2011-09-16 | 2013-05-01 | Merck Sharp & Dohme | 腎外髓質鉀通道抑制劑 |
WO2013062892A1 (en) | 2011-10-25 | 2013-05-02 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US8999991B2 (en) | 2011-10-25 | 2015-04-07 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2013066718A2 (en) | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US9139585B2 (en) | 2011-10-31 | 2015-09-22 | Merck Sharp & Dohme Corp. | Inhibitors of the Renal Outer Medullary Potassium channel |
EP2773206B1 (en) | 2011-10-31 | 2018-02-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2013090271A1 (en) | 2011-12-16 | 2013-06-20 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
JPWO2013147026A1 (ja) | 2012-03-29 | 2015-12-14 | 武田薬品工業株式会社 | 芳香環化合物 |
AR092031A1 (es) | 2012-07-26 | 2015-03-18 | Merck Sharp & Dohme | Inhibidores del canal de potasio medular externo renal |
GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
EP2925322B1 (en) | 2012-11-29 | 2018-10-24 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
EP2934533B1 (en) | 2012-12-19 | 2017-11-15 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US9604998B2 (en) | 2013-02-18 | 2017-03-28 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
EP2968288B1 (en) | 2013-03-15 | 2018-07-04 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
EA201591931A1 (ru) | 2013-04-09 | 2016-05-31 | Ликсте Байотекнолоджи, Инк. | Композиции оксабициклогептанов и оксабициклогептенов |
US9751881B2 (en) | 2013-07-31 | 2017-09-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US9951052B2 (en) | 2013-10-31 | 2018-04-24 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
AU2014369446C1 (en) | 2013-12-20 | 2020-03-12 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
US10426815B2 (en) | 2015-01-20 | 2019-10-01 | The General Hospital Corporation | Prevention and treatment of itch with an MRGPR antagonist |
WO2016127358A1 (en) | 2015-02-12 | 2016-08-18 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
EP4119141A1 (en) | 2015-06-12 | 2023-01-18 | Axovant Sciences GmbH | Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder |
JP2018520187A (ja) | 2015-07-15 | 2018-07-26 | アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH | 神経変性疾患と関連する幻覚の予防および処置のために有用な5−ht2aセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE276541C (ja) * | ||||
AU2859984A (en) | 1983-05-23 | 1984-11-29 | Usv Pharmaceutical Corp. | Compounds for treating hypertension |
US6100048A (en) | 1992-04-10 | 2000-08-08 | Oregon Health Sciences University | Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals |
AU692977B2 (en) | 1994-11-07 | 1998-06-18 | Pfizer Inc. | Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands |
JP2000515151A (ja) | 1996-07-23 | 2000-11-14 | ニューロジェン・コーポレーション | 特定の置換ベンジルアミン誘導体;新規クラスの神経ペプチド―y1特異的リガンド |
WO1998003492A1 (en) | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
DK0918761T3 (da) | 1996-07-23 | 2003-08-25 | Neurogen Corp | Visse amido- og aminosubstituerede benzylaminderivater, en ny klasse af neuropeptid Y1-specifikke ligander |
DE69935159T2 (de) | 1998-12-28 | 2007-10-25 | Takeda Pharmaceutical Co. Ltd. | Screening-verfahren |
US6221613B1 (en) | 1998-12-31 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof |
US7198910B1 (en) | 1999-07-14 | 2007-04-03 | Merck & Co., Inc. | Nucleic acid encoding melanin-concentrating hormone receptor |
EP1218336A2 (en) | 1999-09-20 | 2002-07-03 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
EP1219294A4 (en) | 1999-09-20 | 2005-01-26 | ANTAGONISTS OF THE MELANIN CONCENTRATING HORMON | |
GB0001447D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
MXPA03000174A (es) | 2000-07-06 | 2003-09-22 | Neurogen Corp | Ligandos de receptor de hormona concentradora de melanina. |
WO2002051809A1 (en) | 2000-12-22 | 2002-07-04 | Schering Corporation | Piperidine mch antagonists and their use in the treatment of obesity |
DE10123958A1 (de) | 2001-05-17 | 2002-11-28 | Aventis Pharma Gmbh | Verfahren zur Identifizierung von Liganden für G protein coupled receptors |
BR0209932A (pt) | 2001-05-22 | 2004-10-13 | Neurogen Corp | Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, preparação farmacêutica embalada, métodos para modular ligação de mch a um receptor de mch e de mvc, para alterar a atividade de transdução de sinal de um receptor de mch em uma célula, para tratar uma doença ou distúrbio associado com a ativação de receptor de mch patogênico obesidade e para determinar a presença ou ausência de receptor de mch em uma amostra, e, uso de um composto |
US6552188B2 (en) * | 2001-06-29 | 2003-04-22 | Kowa Co., Ltd. | Unsymmetrical cyclic diamine compound |
DE10139416A1 (de) | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
AU2002352878B2 (en) | 2001-11-27 | 2007-11-22 | Merck Sharp & Dohme Corp. | 2-Aminoquinoline compounds |
US6818772B2 (en) | 2002-02-22 | 2004-11-16 | Abbott Laboratories | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
US20040180889A1 (en) * | 2002-03-01 | 2004-09-16 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
AU2003226927A1 (en) | 2002-04-09 | 2003-10-27 | 7Tm Pharma A/S | Novel carboxamide compounds for use in mch receptor related disorders |
WO2003087046A1 (en) | 2002-04-09 | 2003-10-23 | 7Tm Pharma A/S | Novel aminotetraline compounds for use in mch receptor related disorders |
US7078430B2 (en) | 2002-07-08 | 2006-07-18 | Ranbaxy Laboratories Limited | HMG CoA-reductase inhibitors |
FR2842524B1 (fr) | 2002-07-16 | 2005-04-22 | Aventis Pharma Sa | Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments |
US7091235B2 (en) | 2002-10-15 | 2006-08-15 | Signal Pharmaceuticals, Llc | Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer |
-
2004
- 2004-08-11 AU AU2004266233A patent/AU2004266233A1/en not_active Abandoned
- 2004-08-11 MX MXPA06001636A patent/MXPA06001636A/es unknown
- 2004-08-11 WO PCT/US2004/026021 patent/WO2005019167A2/en active Application Filing
- 2004-08-11 US US10/916,011 patent/US7514438B2/en not_active Expired - Fee Related
- 2004-08-11 CA CA002533112A patent/CA2533112A1/en not_active Abandoned
- 2004-08-11 EP EP04780799A patent/EP1653960A4/en not_active Withdrawn
- 2004-08-11 JP JP2006523335A patent/JP2007502287A/ja not_active Withdrawn
-
2009
- 2009-02-06 US US12/367,083 patent/US7659276B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007502287A5 (ja) | ||
WO2006066173A3 (en) | Novel mch receptor antagonists | |
WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
CA2429844A1 (en) | Mch antagonists and their use in the treatment of obesity | |
JP2008513510A5 (ja) | ||
JP2005506370A5 (ja) | ||
JP2006526031A5 (ja) | ||
JP2005523254A5 (ja) | ||
EP2397476A3 (en) | Indole derivative having PGD2 receptor antagonist activity | |
CA2503767A1 (en) | Pyridopyrrolizine and pyridoindolizine derivatives | |
WO2007146758A3 (en) | Novel mch receptor antagonists | |
JP2007514005A5 (ja) | ||
WO2006023460A3 (en) | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | |
WO2005082871A3 (de) | Guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren | |
WO2007039462A3 (en) | Indane derivatives as mch receptor antagonists | |
WO2008094992A3 (en) | 2-aminopyridine derivatives useful as kinase inhibitors | |
JP2010526777A5 (ja) | ||
WO2007062999A3 (en) | 1,5-substituted indol-2-yl amide derivatives | |
CA2472954A1 (en) | Aza-arylpiperazines | |
WO2009010871A3 (en) | Pyrazole derivatives as antagonists of adenosine a3 receptor | |
WO2008001195A3 (en) | Novel processes for the preparation of dpp iv inhibitors | |
JP2009538861A5 (ja) | ||
WO2003024401A3 (en) | Piperizinones as modulators of chemokine receptor activity | |
CA2503718A1 (en) | Use of serotonin receptor antagonists for the treatment of sleep apnea | |
WO2007053495A3 (en) | Compounds useful as antagonists of ccr2 |